BACKGROUND: Low-grade serous ovarian and peritoneal cancer (LGSC) is a rare disease and few data on the clinical and genomic landscape have been published.METHODS: A retrospective analysis of patients diagnosed with LGSC between 1996 and 2019 was conducted in MITO centers. Objective Response Rate (ORR) to treatments, progression-free survival (PFS) and overall survival (OS) were assessed. Additionally, the tumor molecular profile of 56 patients was evaluated using the Next Generation Sequencing (NGS) FoundationOne CDX (Foundation Medicine (R)).RESULTS: A total of 128 patients with complete clinical data and pathologically confirmed diagnosis of LGSC were identified. ORR to first and subsequent therapies were 23.7% and 33.7%, respectively. PFS was 43.9 months (95% CI:32.4-53.1) and OS was 105.4 months (95% CI: 82.7-not reached). The most common gene alterations were: KRAS (n = 12, 21%), CDKN2A/B (n = 11, 20%), NRAS (n = 8, 14%), FANCA (n = 8, 14%), NF1 (n = 7, 13%) and BRAF (n = 6, 11%). Unexpectedly, pathogenetic BRCA1 (n = 2, 4%), BRCA2 (n = 1, 2%) and PALB2 (n = 1, 2%) mutations were found.CONCLUSIONS: MITO 22 suggests that LGSC is an heterogenous disease for both its clinical behavior in response to standard therapies and its molecular alterations. Future prospective studies should test treatments according to biological and molecular tumor's characteristics.

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

Canzonieri, Vincenzo;
2022

Abstract

BACKGROUND: Low-grade serous ovarian and peritoneal cancer (LGSC) is a rare disease and few data on the clinical and genomic landscape have been published.METHODS: A retrospective analysis of patients diagnosed with LGSC between 1996 and 2019 was conducted in MITO centers. Objective Response Rate (ORR) to treatments, progression-free survival (PFS) and overall survival (OS) were assessed. Additionally, the tumor molecular profile of 56 patients was evaluated using the Next Generation Sequencing (NGS) FoundationOne CDX (Foundation Medicine (R)).RESULTS: A total of 128 patients with complete clinical data and pathologically confirmed diagnosis of LGSC were identified. ORR to first and subsequent therapies were 23.7% and 33.7%, respectively. PFS was 43.9 months (95% CI:32.4-53.1) and OS was 105.4 months (95% CI: 82.7-not reached). The most common gene alterations were: KRAS (n = 12, 21%), CDKN2A/B (n = 11, 20%), NRAS (n = 8, 14%), FANCA (n = 8, 14%), NF1 (n = 7, 13%) and BRAF (n = 6, 11%). Unexpectedly, pathogenetic BRCA1 (n = 2, 4%), BRCA2 (n = 1, 2%) and PALB2 (n = 1, 2%) mutations were found.CONCLUSIONS: MITO 22 suggests that LGSC is an heterogenous disease for both its clinical behavior in response to standard therapies and its molecular alterations. Future prospective studies should test treatments according to biological and molecular tumor's characteristics.
22-lug-2022
Pubblicato
https://www.nature.com/articles/s41416-022-01897-1
File in questo prodotto:
File Dimensione Formato  
s41416-022-01897-1.pdf

non disponibili

Tipologia: Documento in Versione Editoriale
Licenza: Copyright Editore
Dimensione 361.71 kB
Formato Adobe PDF
361.71 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
41416_2022_1897_MOESM1_ESM.pdf

non disponibili

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 206.47 kB
Formato Adobe PDF
206.47 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
41416_2022_1897_MOESM2_ESM.pdf

non disponibili

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 147.89 kB
Formato Adobe PDF
147.89 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
41416_2022_1897_MOESM3_ESM.pdf

non disponibili

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 155.18 kB
Formato Adobe PDF
155.18 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
41416_2022_1897_MOESM4_ESM.pdf

non disponibili

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 148.72 kB
Formato Adobe PDF
148.72 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
41416_2022_1897_MOESM5_ESM.pdf

non disponibili

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 152 kB
Formato Adobe PDF
152 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
41416_2022_1897_MOESM6_ESM.pdf

non disponibili

Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 167.52 kB
Formato Adobe PDF
167.52 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/3028344
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact